Follow The Filings

QURE uniQure

uniQure earnings company data as of 4:47 AM ET 10/22

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 9 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by QURE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All QURE insider trades
  • None no insider bought on the open market
  • None no sales outside a trading plan
  • $19.7M sold by 5 insiders under 10b5-1 plans
  1. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $952K 21,082 shares at $45.16 3.9% of stake
    Traded Jul 2 Filed Jul 7
    ↗
  2. Walid Abi-Saab Chief Medical Officer
    Planned sale
    $1.4M 30,000 shares at $46.42 17% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  3. Jack Kaye Director
    Planned sale
    $983K 21,167 shares at $46.44 45% of stake
    Traded Jun 30 Filed Jul 2
    ↗
  4. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $1.8M 35,412 shares at $50.02 6.4% of stake
    Traded Jun 24–25 Filed Jun 26
    ↗
  5. Matthew C Kapusta CEO, Managing Director
    Planned sale
    $9.4M 206,100 shares at $45.47 28% of stake
    Traded Jun 17–18 Filed Jun 22
    ↗
  6. Madhavan Balachandran Director
    Planned sale
    $526K 11,685 shares at $45.06 21% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  7. Jack Kaye Director
    Planned sale
    $225K 5,295 shares at $42.57 17% of stake
    Traded Jun 17 Filed Jun 22
    ↗
  8. Madhavan Balachandran Director
    Planned sale
    $279K 10,000 shares at $27.85 19% of stake
    Traded Jun 15 Filed Jun 17
    ↗
  9. Robert Gut Director
    Planned sale
    $197K 7,552 shares at $26.05 22% of stake
    Traded Jun 10 Filed Jun 12
    ↗
  10. Jack Kaye Director
    Planned sale
    $79K 2,645 shares at $30.01 12% of stake
    Traded Jun 3 Filed Jun 5
    ↗
  11. Walid Abi-Saab Chief Medical Officer
    Planned sale
    $1.1M 45,000 shares at $25.06 21% of stake
    Traded May 8 Filed May 12
    ↗
  12. Robert Gut Director
    Planned sale
    $630K 25,613 shares at $24.62 44% of stake
    Traded Jan 12 Filed Jan 14
    ↗
  13. Jack Kaye Director
    Planned sale
    $174K 6,390 shares at $27.28 24% of stake
    Traded Jan 9 Filed Jan 12
    ↗
  14. Robert Gut Director
    Planned sale
    $857K 31,434 shares at $27.26 44% of stake
    Traded Nov 6, 2025 Filed Nov 10, 2025
    ↗
  15. Jack Kaye Director
    Planned sale
    $1.2M 38,810 shares at $30.34 66% of stake
    Traded Nov 4, 2025 Filed Nov 6, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 20 sales to cover taxes, and 12 stock grants.

SEC filings

Recent issuer filings from EDGAR, 20 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,5.03,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.